Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia

Purpose To assess the prevalence of sarcopenia and whether body composition parameters are associated with disease progression and overall survival (OS) in castration-resistant prostate cancer (CRPC) patients. Materials and methods This single-centre retrospective study evaluated data of 186 consecu...

Full description

Saved in:
Bibliographic Details
Published in:Prostate cancer and prostatic diseases 2020-06, Vol.23 (2), p.309-315
Main Authors: Stangl-Kremser, Judith, Suarez‐Ibarrola, Rodrigo, Andrea, David D’, Korn, Stephan M., Pones, Mario, Kramer, Gero, Marhold, Maximilian, Krainer, Michael, Enikeev, Dmitry V., Glybochko, Petr V., Tamandl, Dietmar, Shariat, Shahrokh F., Baltzer, Pascal
Format: Article
Language:English
Subjects:
692/53/2422
692/699/67
Aged
Antineoplastic Agents - adverse effects
Biomedical and Life Sciences
Biomedicine
Body Composition
Cancer
Cancer Research
Care and treatment
Castration
Chemotherapy
Computed tomography
CT imaging
Decision making
Development and progression
Docetaxel - adverse effects
Follow-Up Studies
Humans
Liver
Liver cancer
Male
Mathematical analysis
Medical prognosis
Medical research
Medicine, Experimental
Metastases
Metastasis
Middle Aged
Muscle, Skeletal - drug effects
Muscle, Skeletal - pathology
Muscles
Musculoskeletal system
Parameters
Physiological aspects
Prognosis
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Retrospective Studies
Sarcopenia
Sarcopenia - chemically induced
Sarcopenia - pathology
Skeletal muscle
Statistical analysis
Survival Rate
Technology application
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To assess the prevalence of sarcopenia and whether body composition parameters are associated with disease progression and overall survival (OS) in castration-resistant prostate cancer (CRPC) patients. Materials and methods This single-centre retrospective study evaluated data of 186 consecutive patients who underwent chemohormonal therapy between 2005 and 2016 as first-line systemic treatment for CRPC. Skeletal muscle and fat indices were determined using computerized tomography data before initiation of chemotherapy. Sarcopenia was defined as SMI of
ISSN:1365-7852
1476-5608
DOI:10.1038/s41391-019-0186-6